Zymeworks Inc
NASDAQ:ZYME
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.11
17.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Zymeworks Inc
Other Liabilities
Zymeworks Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Zymeworks Inc
NASDAQ:ZYME
|
Other Liabilities
$32.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$33B
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
28%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$24.4B
|
CAGR 3-Years
63%
|
CAGR 5-Years
29%
|
CAGR 10-Years
39%
|
||
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$4.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-4%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$2.5B
|
CAGR 3-Years
56%
|
CAGR 5-Years
50%
|
CAGR 10-Years
44%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$1.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
See Also
What is Zymeworks Inc's Other Liabilities?
Other Liabilities
32.8m
USD
Based on the financial report for Sep 30, 2024, Zymeworks Inc's Other Liabilities amounts to 32.8m USD.
What is Zymeworks Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-4%
Over the last year, the Other Liabilities growth was -43%. The average annual Other Liabilities growth rates for Zymeworks Inc have been -20% over the past three years , -4% over the past five years .